health. INFUSION CARE

UPLIZNA Infusion Orders

PHONE 515.225.2930 | **FAX** 515.559.2495

Patient Info	rmation	Fax completed form i	nsurance infor	mation and clinical docu	mentation to 515.559.2495.	
Patient Status:	New to Therapy	Continuing Therapy	DOB Next Treatm			
Patient Status.	New to merapy		Next Heath			
Medical Info	rmation					
Diagnosis:	Neuromyelitis optica spectrum disorder	(ICD-10 Code: G36)				
		(ICD-10 Code:)		
	Other:	(ICD-10 COde)		
Patient weight:	lbs.	Allergies:				
Therapy Ord	er					
Uplizna						
Initial dosing: 300 mg IV followed by 300 mg IV 2 weeks later, then 300 mg IV every 6 months						
(starting 6 months from the first infusion) x1 year						
300 mg IV ev	rery 6 months x1 year					
Protocol premedication orders: Solu-Medrol 125 mg IV, Benadryl 25 mg PO and Tylenol 650 mg PO to be given 30 minutes prior to infusion						
	(if no contraindication	15)				
Other orders: _						
Lab Orders:		Lak	Frequency:			
Required labs to be drawn by: Infusion Center Referring Provider						
Anaphylactic rea	action orders:					
Epinephrine (based on patient weight)						
 >30kg (>66lbs): EpiPen 0.3 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1 						
 15-30kg (33-66lbs): EpiPen Jr. 0.15 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1 						
• Diphenhydramine: Administer 25-50 mg PO or IV (adult)						
Refer to physician order or institutional protocol for pediatric dosing as applicable						
Flush orders: NS 1-20 mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN						
Physician In	formation					
By signing this form and utilizing our services, you are authorizing Hy-Vee Health and its employees to serve as your prior authorization and specialty pharmacy						
	nt in dealing with medical and prescript					
Provider Name:		Signature:			Date:	
Provider NPI:	Phone:	Fax:		Contact Person:		
Opt out of Hy	-Vee Health selecting site of care (if che	ecked, please list site of care):				
Service Areas						
Service Area	S					
Des Moines,	IA West Des Moines, IA Chic	cago, IL Omaha, NE	Buffalo, NY	Dallas, TX Phoenix, AZ	Other	
		HY-VEEHEALTHINFU	SION.COM			

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR UPLIZNA THERAPY

Patient Information

Patient Name: DOB:					
Required Documentation for Referral Processing & Insurance Approval					
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)					
Include patient demographic information and insurance information					
Include patient's current medication list					
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy					
Has the patient had a documented contraindication/intolerance or failed trial of Rituximab, Azathioprine or Mycophenolate Mofetil?					
Yes No					
Does the patient have a history of at least 1 relapse (acute attack from neuromyelitis spectrum disorder) in the last 12 months, or 2 relapses in the last 2 years? Yes No					
Expanded Disability Status Score (EDSS):					
Include labs and/or test results to support diagnosis					
Other medical necessity:					
Required Prescreening					
TB screening test completed within 12 months – attach results Positive Negative					
Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) – attach results Positive Negative					
Serum immunoglobulins – attach results					

AQP4 positive antibody lab – attach results

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.